Showing results (51-60 of 146) with videos related to

Sort By:
Pageof 15
Human Mutation|August 7, 2007
Rapid identification of disease-causing mutations using copy number analysis within linkage intervalsFatih Bayrakli, Kaya Bilguvar, Christopher E Mason, et al.
Multiple Sclerosis and Related Disorders|April 30, 2026
Beyond serology: clinical and prognostic determinants in patients with dual AQP4-IgG and MOG-IgG seropositivityIpek Gungor Dogan, Sedat Sen, Damla Cetinkaya Tezer, et al.
Multiple Sclerosis and Related Disorders|September 7, 2023
Severe disease reactivation in seropositive neuromyelitis optica spectrum disorders patients after stopping eculizumab treatmentSedat Sen, Asli Tuncer, Murat Terzi, et al.
EMBO Reports|November 3, 2020
Inositol-requiring enzyme-1 regulates phosphoinositide signaling lipids and macrophage growthSyed Muhammad Hamid, Mevlut Citir, Erdem Murat Terzi, et al.
Multiple Sclerosis and Related Disorders|April 2, 2018
Prevalence of and risk factors for cognitive impairment in patients with relapsing-remitting multiple sclerosis: Multi-center, controlled trialSerkan Ozakbas, Recai Turkoglu, Yusuf Tamam, et al.
The New England Journal of Medicine|May 4, 2019
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum DisorderSean J Pittock, Achim Berthele, Kazuo Fujihara, et al.
International Journal of Clinical Practice|March 20, 2021
The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from TurkeyCihat Uzunköprü, Melih Tütüncü, Tuncay Gündüz, et al.
CNS Drugs|June 24, 2021
Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018Nahid Moradi, Sifat Sharmin, Charles Malpas, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 30, 2022
External validation of a clinical prediction model in multiple sclerosisNahid Moradi, Sifat Sharmin, Charles B Malpas, et al.
Multiple Sclerosis and Related Disorders|December 14, 2020
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trialJacqueline Palace, Dean M Wingerchuk, Kazuo Fujihara, et al.
Pageof 15